Subscribe via RSS- NEWS ARCHIVES
-
2008
2007
2006
2005
2004
Pharma & Bio Ingredients
Amgen announced today that adjusted net income rose 24 percent to $928 million. Full year 2005 adjusted net income ros 28 percent to $4.0 billion.
Total revenue increased 12 percent during the fourth quarter of 2005 to $3.3 billion and 18 percent for the full year to $12.4 billion.
"2005 was another strong year for Amgen," said Kevin Sharer, Amgen's chairman and chief executive officer. "In addition to delivering financially, we achieved four major regulatory milestones and added six new molecules to our pipeline. We made significant progress in advancing our late stage pipeline. Also during the fourth quarter, we received positive data from a pivotal trial with panitumumab, which could potentially advance the treatment of colorectal cancer. This contributed to our strategic decision to acquire Abgenix," concluded Sharer.
